Cargando…
The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537682/ https://www.ncbi.nlm.nih.gov/pubmed/36211357 http://dx.doi.org/10.3389/fimmu.2022.994053 |
_version_ | 1784803260386770944 |
---|---|
author | Peng, Xiaohuan Zhu, Xiaofeng Di, Tianning Tang, Futian Guo, Xiaojia Liu, Yang Bai, Jun Li, Yanhong Li, Lijuan Zhang, Liansheng |
author_facet | Peng, Xiaohuan Zhu, Xiaofeng Di, Tianning Tang, Futian Guo, Xiaojia Liu, Yang Bai, Jun Li, Yanhong Li, Lijuan Zhang, Liansheng |
author_sort | Peng, Xiaohuan |
collection | PubMed |
description | Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS) is mainly characterized by immune hyperfunction and increased apoptosis, and the immunosuppressive therapy shows a good response. Instead, higher-risk MDS (HR-MDS) is characterized by immune suppression and immune escape, and the immune activation therapy may improve the survival of HR-MDS. Furthermore, the immune dysregulation of some MDS changes dynamically which is characterized by the coexistence and mutual transformation of immune hyperfunction and immune suppression. Taken together, the authors think that the immune dysregulation in MDS with different risk stratification can be summarized by an advanced philosophical thought “Yin-Yang theory” in ancient China, meaning that the opposing forces may actually be interdependent and interconvertible. Clarifying the mechanism of immune dysregulation in MDS with different risk stratification can provide the new basis for diagnosis and clinical treatment. This review focuses on the manifestations and roles of immune dysregulation in the different risk MDS, and summarizes the latest progress of immunotherapy in MDS. |
format | Online Article Text |
id | pubmed-9537682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95376822022-10-08 The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification Peng, Xiaohuan Zhu, Xiaofeng Di, Tianning Tang, Futian Guo, Xiaojia Liu, Yang Bai, Jun Li, Yanhong Li, Lijuan Zhang, Liansheng Front Immunol Immunology Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid clonal diseases with diverse clinical courses, and immune dysregulation plays an important role in the pathogenesis of MDS. However, immune dysregulation is complex and heterogeneous in the development of MDS. Lower-risk MDS (LR-MDS) is mainly characterized by immune hyperfunction and increased apoptosis, and the immunosuppressive therapy shows a good response. Instead, higher-risk MDS (HR-MDS) is characterized by immune suppression and immune escape, and the immune activation therapy may improve the survival of HR-MDS. Furthermore, the immune dysregulation of some MDS changes dynamically which is characterized by the coexistence and mutual transformation of immune hyperfunction and immune suppression. Taken together, the authors think that the immune dysregulation in MDS with different risk stratification can be summarized by an advanced philosophical thought “Yin-Yang theory” in ancient China, meaning that the opposing forces may actually be interdependent and interconvertible. Clarifying the mechanism of immune dysregulation in MDS with different risk stratification can provide the new basis for diagnosis and clinical treatment. This review focuses on the manifestations and roles of immune dysregulation in the different risk MDS, and summarizes the latest progress of immunotherapy in MDS. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9537682/ /pubmed/36211357 http://dx.doi.org/10.3389/fimmu.2022.994053 Text en Copyright © 2022 Peng, Zhu, Di, Tang, Guo, Liu, Bai, Li, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Peng, Xiaohuan Zhu, Xiaofeng Di, Tianning Tang, Futian Guo, Xiaojia Liu, Yang Bai, Jun Li, Yanhong Li, Lijuan Zhang, Liansheng The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title | The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title_full | The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title_fullStr | The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title_full_unstemmed | The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title_short | The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification |
title_sort | yin-yang of immunity: immune dysregulation in myelodysplastic syndrome with different risk stratification |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537682/ https://www.ncbi.nlm.nih.gov/pubmed/36211357 http://dx.doi.org/10.3389/fimmu.2022.994053 |
work_keys_str_mv | AT pengxiaohuan theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT zhuxiaofeng theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT ditianning theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT tangfutian theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT guoxiaojia theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT liuyang theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT baijun theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT liyanhong theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT lilijuan theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT zhangliansheng theyinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT pengxiaohuan yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT zhuxiaofeng yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT ditianning yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT tangfutian yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT guoxiaojia yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT liuyang yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT baijun yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT liyanhong yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT lilijuan yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification AT zhangliansheng yinyangofimmunityimmunedysregulationinmyelodysplasticsyndromewithdifferentriskstratification |